The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b study of sotorasib combined with panitumumab as second-line treatment of KRAS G12C-mutated colorectal cancer.
 
Rona Yaeger
Honoraria - Zai Lab
Consulting or Advisory Role - Mirati Therapeutics
Research Funding - Boehringer Ingelheim (Inst); Daiichi Sankyo/UCB Japan (Inst); Daiichi Sankyo/UCB Japan (Inst); Mirati Therapeutics (Inst); Pfizer (Inst)
 
Corey J. Langer
Honoraria - AstraZeneca; Genentech/Roche; Lilly/ImClone; Merck; Takeda Science Foundation
Consulting or Advisory Role - Abbott Biotherapeutics; ARIAD/Merck; AstraZeneca; Bayer/Onyx; Bristol-Myers Squibb; Cancer Support Community; Celgene; Clarient; Clovis Oncology; Genentech/Roche; Gilead Sciences; Lilly/ImClone; Merck; Novocure; Pfizer; Regeneron; Takeda
Research Funding - Advantagene (Inst); Amgen; ARIAD (Inst); AstraZeneca; Celgene (Inst); Clovis Oncology GmbH (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte; Inovio Pharmaceuticals (Inst); Johnson & Johnson/Janssen; Lilly; Merck (Inst); Stem CentRx (Inst); Trizell (Inst)
 
Jose Carlos Ruffinelli
Travel, Accommodations, Expenses - MSD
 
Marwan Fakih
Honoraria - Amgen
Consulting or Advisory Role - Amgen; Bayer; BMS; Eisai; GlaxoSmithKline; Incyte; Merck; Mirati Therapeutics; Nouscom; Pfizer; Roche/Genentech; Seagen; Taiho Pharmaceutical
Speakers' Bureau - Guardant Health
Research Funding - Amgen (Inst); Verastem (Inst)
 
Muhammad Furqan
Consulting or Advisory Role - Abbvie; AstraZeneca/MedImmune; BeiGene; BeiGene; Jazz Pharmaceuticals; Mirati Therapeutics; Novartis; Omega Therapeutics
Research Funding - Abbvie (Inst); Abbvie/Stemcentrx (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Biothera (Inst); Bristol-Myers Squibb/Celgene (Inst); Celgene (Inst); Checkmate Pharmaceuticals (Inst); Elicio Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Jacobus Pharmaceutical Company (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst)
 
Jean-Pascal H. Machiels
Leadership - European Organisation for Research and Treatment of Cancer (EORTC)
Consulting or Advisory Role - ALX Oncology (Inst); Astellas Oncology (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Cue Biopharma (Inst); CureVac (Inst); Etherna (Inst); F-Star (Inst); Genmab (Inst); Incyte (Inst); Innate Pharma (Inst); iTEOS Therapeutics (Inst); Janssen (Inst); Merck Serono (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Gilead Sciences; MSD; Pfizer; Sanofi
 
Yaneth Saportas
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Jane Nolte-Hippenmeyer
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Emily Chan
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Caihong Xia
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Toshiki Masuishi
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; MSD; Nippon Kayaku; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Amgen (Inst); Boehringer Ingelheim (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Syneos Health (Inst)